Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02298322 · ClinicalTrials.gov registry record · NA
Subcutaneous Fat Reduction in the Submental Area
A NA study of Body Fat Disorder, sponsored by Zeltiq Aesthetics.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT02298322 is a NA study of Body Fat Disorder that has completed, run by Zeltiq Aesthetics. The registered enrollment target is 60 participants, above the 28-participant average among 3 other Body Fat Disorder trials with a reported enrollment target (114% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT02298322, a NA study of Body Fat Disorder, has completed, sponsored by Zeltiq Aesthetics.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
Study to Evaluate Non-Invasive Subcutaneous Fat Reduction in the Submental Area using Cryolipolysis. Healthy adult men and women with submental skin fold thickness \> 1cm who desire reduction of submental fat.
Conditions Studied
Interventions
- DEVICE CoolSculpting System
Study Locations (3)
California
- Laser & Skin Surgery Center of Northern California - Sacramento
Minnesota
- Zel Skin & Laser Specialists - Edina
Texas
- EpiCentre Skin and Laser Center - Plano
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-11-11 |
| Est. Completion | 2015-08-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02298322
The ClinicalTrials.gov registry entry for NCT02298322 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 28-participant average among 3 other Body Fat Disorder trials with a reported enrollment target (114% higher). The listed sponsor is Zeltiq Aesthetics, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Body Fat Disorder appearing as the primary indexed condition, and to 1 intervention - of which CoolSculpting System is the first listed.
NCT02298322 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT02298322 about?
NCT02298322 is a clinical study titled "Subcutaneous Fat Reduction in the Submental Area". Study to Evaluate Non-Invasive Subcutaneous Fat Reduction in the Submental Area using Cryolipolysis. Healthy adult men and women with submental skin fold thickness \> 1cm who desire reduction of submental fat.
What is the current status of trial NCT02298322?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2014-11-11. Estimated completion is 2015-08-02.
What conditions does trial NCT02298322 study?
This clinical trial studies the following conditions: Body Fat Disorder.
What interventions are being tested in trial NCT02298322?
The interventions under investigation include: CoolSculpting System (DEVICE).
Who is sponsoring clinical trial NCT02298322?
This trial is sponsored by Zeltiq Aesthetics, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02298322 being conducted?
This trial has 3 study locations across California, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Body Fat Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.